JP7228318B6 - 処置用化合物及び組成物、並びにその使用方法 - Google Patents

処置用化合物及び組成物、並びにその使用方法 Download PDF

Info

Publication number
JP7228318B6
JP7228318B6 JP2019564529A JP2019564529A JP7228318B6 JP 7228318 B6 JP7228318 B6 JP 7228318B6 JP 2019564529 A JP2019564529 A JP 2019564529A JP 2019564529 A JP2019564529 A JP 2019564529A JP 7228318 B6 JP7228318 B6 JP 7228318B6
Authority
JP
Japan
Prior art keywords
compounds
alkyl
pharmaceutically acceptable
group
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019564529A
Other languages
English (en)
Japanese (ja)
Other versions
JP7228318B2 (ja
JP2020520957A (ja
JP2020520957A5 (https=
Inventor
ザック，マーク
ロメロ，エフ・アンソニー
チェン，ユン－シン
リ，ウェイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2020520957A publication Critical patent/JP2020520957A/ja
Publication of JP2020520957A5 publication Critical patent/JP2020520957A5/ja
Publication of JP7228318B2 publication Critical patent/JP7228318B2/ja
Application granted granted Critical
Publication of JP7228318B6 publication Critical patent/JP7228318B6/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2019564529A 2017-05-22 2018-05-21 処置用化合物及び組成物、並びにその使用方法 Active JP7228318B6 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2017085277 2017-05-22
CNPCT/CN2017/085277 2017-05-22
US201862644784P 2018-03-19 2018-03-19
US62/644,784 2018-03-19
PCT/EP2018/063263 WO2018215390A1 (en) 2017-05-22 2018-05-21 Therapeutic compounds and compositions, and methods of use thereof

Publications (4)

Publication Number Publication Date
JP2020520957A JP2020520957A (ja) 2020-07-16
JP2020520957A5 JP2020520957A5 (https=) 2021-07-26
JP7228318B2 JP7228318B2 (ja) 2023-02-24
JP7228318B6 true JP7228318B6 (ja) 2023-03-10

Family

ID=62486555

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019564529A Active JP7228318B6 (ja) 2017-05-22 2018-05-21 処置用化合物及び組成物、並びにその使用方法

Country Status (6)

Country Link
US (3) US20180334465A1 (https=)
EP (1) EP3630767A1 (https=)
JP (1) JP7228318B6 (https=)
CN (1) CN110678467B (https=)
TW (1) TW201900648A (https=)
WO (1) WO2018215390A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201720828A (zh) * 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
MX387969B (es) 2017-05-22 2025-03-19 Hoffmann La Roche Composiciones y compuestos terapéuticos, y métodos para su uso.
JP2022519696A (ja) * 2019-02-07 2022-03-24 ベンティックス バイオサイエンシーズ，インク． Ｔｙｋ２偽キナーゼリガンド
EA202192575A1 (ru) 2019-03-21 2022-01-14 Онксео Соединения dbait в сочетании с ингибиторами киназ для лечения рака
TW202115069A (zh) 2019-06-18 2021-04-16 瑞士商赫孚孟拉羅股份公司 Ｊａｋ激酶之經四唑取代之吡唑并嘧啶抑制劑及其用途
PH12021552998A1 (en) * 2019-06-18 2023-08-14 Hoffmann La Roche Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4178950A1 (en) 2020-07-07 2023-05-17 Universitat Rovira I Virgili Reagents for the polyfluoroalkylthiolation of organic compounds and method for production thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012532112A (ja) 2009-07-02 2012-12-13 ジェネンテック， インコーポレイテッド ピラゾロピリミジンｊａｋ阻害剤化合物及び方法
WO2017089390A1 (en) 2015-11-23 2017-06-01 F. Hoffmann-La Roche Ag Janus kinases inhibitors, compositions thereof and use thereof
WO2017140825A1 (en) 2016-02-18 2017-08-24 F. Hoffmann-La Roche Ag Therapeutic compounds, compositions and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US6034057A (en) 1995-07-06 2000-03-07 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
DE60214428T2 (de) 2001-12-20 2007-09-20 Bayer Healthcare Ag 1, 4-dihydro-1, 4-diphenylpyridin-derivate
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
CN102131389A (zh) 2008-06-20 2011-07-20 健泰科生物技术公司 三唑并吡啶jak抑制剂化合物和方法
EP2348860B1 (en) 2008-10-31 2015-05-27 Genentech, Inc. Pyrazolopyrimidine jak inhibitor compounds and methods
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
AP2015008433A0 (en) 2012-11-09 2015-05-31 Jacobus Pahrmaceutical Company Inc Heteroaryl derivatives and uses thereof
JP2017516850A (ja) 2014-05-23 2017-06-22 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｊａｋ阻害剤である５−クロロ−２−ジフルオロメトキシフェニルピラゾロピリミジン化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012532112A (ja) 2009-07-02 2012-12-13 ジェネンテック， インコーポレイテッド ピラゾロピリミジンｊａｋ阻害剤化合物及び方法
WO2017089390A1 (en) 2015-11-23 2017-06-01 F. Hoffmann-La Roche Ag Janus kinases inhibitors, compositions thereof and use thereof
JP6914933B2 (ja) 2015-11-23 2021-08-04 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ヤヌスキナーゼ、並びにその組成物及びその使用
WO2017140825A1 (en) 2016-02-18 2017-08-24 F. Hoffmann-La Roche Ag Therapeutic compounds, compositions and methods of use thereof

Also Published As

Publication number Publication date
TW201900648A (zh) 2019-01-01
JP7228318B2 (ja) 2023-02-24
US20220024945A1 (en) 2022-01-27
EP3630767A1 (en) 2020-04-08
WO2018215390A1 (en) 2018-11-29
US20180334465A1 (en) 2018-11-22
US20200062779A1 (en) 2020-02-27
JP2020520957A (ja) 2020-07-16
CN110678467B (zh) 2023-06-13
CN110678467A (zh) 2020-01-10

Similar Documents

Publication Publication Date Title
JP7228318B6 (ja) 処置用化合物及び組成物、並びにその使用方法
JP7256757B2 (ja) 処置用化合物及び組成物、並びにその使用方法
US20230206644A1 (en) Pyrazolopyrimidine compounds as jak inhibitors
CN114026096B (zh) 四唑取代的吡唑并嘧啶类jak激酶抑制剂及其用途
US20230016791A1 (en) Inhalable dry powder and aerosol formulations of jak inhibitors
EP3596072B1 (en) Pyrazolochlorophenyl compounds, compositions and methods of use thereof
CN114008050B (zh) Jak激酶的吡唑并嘧啶芳基醚抑制剂及其用途
EP4198036A1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a] pyridinyl compounds, compositions and methods of use thereof
HK40093207A (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a] pyridinyl compounds, compositions and methods of use thereof
HK40029259A (en) Pyrazolopyrimidine compounds as jak inhibitors
HK40019825A (en) Therapeutic compounds and compositions, and methods of use thereof
HK40019824A (en) Therapeutic compounds and compositions, and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210514

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210514

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220428

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221005

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230117

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230209

R150 Certificate of patent or registration of utility model

Ref document number: 7228318

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150